Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients

Not Applicable

Completed

• Conditions: Corona Virus Infection
• Interventions: Drug: Nitroglycerin

• Registration Number: NCT04686760
• Lead Sponsor: University of Lahore

Brief Summary

In current analysis moderate to severely ill Covid-19 infected patients will be nebulized with nitroglycerin, and they will be compared with the standard nebulization

Detailed Description

Not available

Study Timeline

• Study Start: 2020-11-15
• Study First Submitted: 2020-12-24
• Study First Submitted QC: 2020-12-25
• Study First Posted: 2020-12-29
• Primary Completion: 2021-12-15
• Study Completion: 2022-03-15
• Status Verified: 2022-05
• Last Update Submitted: 2022-05-16
• Last Update Posted: 2022-05-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 278

Inclusion Criteria

Diagnosed admitted cases of Covid-19 degree of illness should be moderate to severe both male and female every age group

Exclusion Criteria

allergic to nitroglycerin sudden drop in blood pressure not given consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Nitroglycerin solution	Nitroglycerin	-

Primary Outcome Measures

Name	Time	Method
ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen	5-7 days
Oxygen demand	5-7 days

Secondary Outcome Measures

Name	Time	Method
Duration of hospital stay	15 days

Trial Locations

Locations (1)

Bahria Town International Hospital; 🇵🇰 Lahore, Punjab, Pakistan